PE20030433A1 - Formulacion liquida que comprende cetuximab - Google Patents
Formulacion liquida que comprende cetuximabInfo
- Publication number
- PE20030433A1 PE20030433A1 PE2002000618A PE2002000618A PE20030433A1 PE 20030433 A1 PE20030433 A1 PE 20030433A1 PE 2002000618 A PE2002000618 A PE 2002000618A PE 2002000618 A PE2002000618 A PE 2002000618A PE 20030433 A1 PE20030433 A1 PE 20030433A1
- Authority
- PE
- Peru
- Prior art keywords
- liquid formulation
- polyoxyethylene
- formulation including
- including cetuximab
- cetuximab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA LIQUIDA QUE COMPRENDE: a) EL ANTICUERPO MONOCLONAL QUIMERICO C225 ( CETUXIMAB ) CONTRA EL RECEPTOR DEL FACTOR DE CRECIMIENTO ENDOTELIAL (RECEPTOR EGF) ; b) DE 2mM A 100 mM DE UN BUFFER FOSFATO Y c) DE 0,005% A 0,1% DE UN ESTER DE ACIDO GRASO DE POLIOXIETILEN SORBITAN SELECCIONADO DE MONOOLEATO DE POLIOXIETILEN (20) SORBITAN O MONOLAURATO DE POLIOXIETILEN (20) SORBITAN. LA FORMULACION TIENE UN pH ENTRE 6,5 A 7,5 Y CONTIENE ADEMAS UN AGENTE ISOTONICO TAL COMO CLORURO DE SODIO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10133394A DE10133394A1 (de) | 2001-07-13 | 2001-07-13 | Flüssige Formulierung enthaltend Cetuximab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030433A1 true PE20030433A1 (es) | 2003-05-24 |
Family
ID=7691220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000618A PE20030433A1 (es) | 2001-07-13 | 2002-07-11 | Formulacion liquida que comprende cetuximab |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040170632A1 (es) |
| EP (1) | EP1406658A1 (es) |
| JP (1) | JP2004536129A (es) |
| KR (1) | KR20040018458A (es) |
| CN (1) | CN1231264C (es) |
| AR (1) | AR039358A1 (es) |
| BR (1) | BR0211060A (es) |
| CA (1) | CA2453342A1 (es) |
| CZ (1) | CZ2004189A3 (es) |
| DE (1) | DE10133394A1 (es) |
| HU (1) | HUP0401046A3 (es) |
| MX (1) | MXPA04000340A (es) |
| PE (1) | PE20030433A1 (es) |
| PL (1) | PL364599A1 (es) |
| RU (1) | RU2004102395A (es) |
| SK (1) | SK862004A3 (es) |
| WO (1) | WO2003007988A1 (es) |
| ZA (1) | ZA200401161B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3417875T1 (sl) * | 2003-02-10 | 2021-01-29 | Biogen Ma Inc. | Formulacija imunoglobulina in metode za njegovo pripravo |
| DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| AU2005211890B2 (en) * | 2004-02-12 | 2011-07-28 | Merck Patent Gmbh | Highly concentrated liquid formulations of anti-EGFR antibodies |
| KR20070008710A (ko) * | 2004-04-27 | 2007-01-17 | 웰스테트 바이올로직스 코포레이션 | 바이러스 및 캄토테신을 이용한 암치료 방법 |
| JP2008519757A (ja) * | 2004-11-12 | 2008-06-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗ｅｇｆｒ抗体の固形物 |
| PT1859793E (pt) * | 2005-02-28 | 2011-07-05 | Eisai R&D Man Co Ltd | Uso combinado inovador de um composto de sulfonamida no tratamento oncológico |
| EP1982718A4 (en) | 2006-02-09 | 2010-05-12 | Daiichi Sankyo Co Ltd | ANTICANCER PHARMACEUTICAL COMPOSITION |
| EP2015775B1 (en) | 2006-05-03 | 2011-06-01 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| TW200831129A (en) * | 2006-10-06 | 2008-08-01 | Amgen Inc | Stable formulations |
| AU2007309616B2 (en) * | 2006-10-20 | 2011-10-06 | Amgen Inc. | Stable polypeptide formulations |
| CN107773755B (zh) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | 抗表皮生长因子受体单克隆抗体的注射液制剂 |
| WO2018211517A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| CN112566652A (zh) | 2018-06-25 | 2021-03-26 | Jcr制药股份有限公司 | 含有蛋白的水性液体制剂 |
| US20210290644A1 (en) * | 2018-08-31 | 2021-09-23 | Amplyx Pharmaceuticals, Inc. | Compounds and methods for treating fungal infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| AU6267896A (en) * | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| IL122910A (en) * | 1995-07-27 | 2002-05-23 | Genentech Inc | Stable isotonic protein formulation that has undergone lyophilization |
-
2001
- 2001-07-13 DE DE10133394A patent/DE10133394A1/de not_active Withdrawn
-
2002
- 2002-06-18 MX MXPA04000340A patent/MXPA04000340A/es unknown
- 2002-06-18 BR BR0211060-1A patent/BR0211060A/pt not_active IP Right Cessation
- 2002-06-18 CN CNB028141059A patent/CN1231264C/zh not_active Expired - Fee Related
- 2002-06-18 HU HU0401046A patent/HUP0401046A3/hu unknown
- 2002-06-18 US US10/483,404 patent/US20040170632A1/en not_active Abandoned
- 2002-06-18 WO PCT/EP2002/006696 patent/WO2003007988A1/de not_active Application Discontinuation
- 2002-06-18 KR KR10-2004-7000530A patent/KR20040018458A/ko not_active Application Discontinuation
- 2002-06-18 RU RU2004102395/15A patent/RU2004102395A/ru not_active Application Discontinuation
- 2002-06-18 PL PL02364599A patent/PL364599A1/xx unknown
- 2002-06-18 SK SK86-2004A patent/SK862004A3/sk not_active Application Discontinuation
- 2002-06-18 CA CA002453342A patent/CA2453342A1/en not_active Abandoned
- 2002-06-18 EP EP02751038A patent/EP1406658A1/de not_active Withdrawn
- 2002-06-18 JP JP2003513593A patent/JP2004536129A/ja not_active Withdrawn
- 2002-06-18 CZ CZ2004189A patent/CZ2004189A3/cs unknown
- 2002-07-11 PE PE2002000618A patent/PE20030433A1/es not_active Application Discontinuation
- 2002-07-12 AR ARP020102605A patent/AR039358A1/es unknown
-
2004
- 2004-02-12 ZA ZA200401161A patent/ZA200401161B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0401046A2 (en) | 2006-04-28 |
| ZA200401161B (en) | 2004-10-22 |
| RU2004102395A (ru) | 2005-05-27 |
| CZ2004189A3 (cs) | 2004-05-12 |
| BR0211060A (pt) | 2004-07-20 |
| EP1406658A1 (de) | 2004-04-14 |
| HUP0401046A3 (en) | 2006-11-28 |
| MXPA04000340A (es) | 2004-05-04 |
| CN1231264C (zh) | 2005-12-14 |
| PL364599A1 (en) | 2004-12-13 |
| DE10133394A1 (de) | 2003-01-30 |
| AR039358A1 (es) | 2005-02-16 |
| CN1527724A (zh) | 2004-09-08 |
| KR20040018458A (ko) | 2004-03-03 |
| SK862004A3 (en) | 2004-07-07 |
| WO2003007988A1 (de) | 2003-01-30 |
| US20040170632A1 (en) | 2004-09-02 |
| CA2453342A1 (en) | 2003-01-30 |
| JP2004536129A (ja) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030433A1 (es) | Formulacion liquida que comprende cetuximab | |
| PE20090738A1 (es) | Formulaciones de anticuerpos | |
| AU3438900A (en) | Use of trehalose for stabilising a liquid vaccine | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| MA27551A1 (fr) | Composition immunogene | |
| JO2481B1 (en) | Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods | |
| IL153406A0 (en) | Cyclopentanoindoles, compositions containing such compounds and methods of treatment | |
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| AR092919A2 (es) | Composicion farmaceutica liquida | |
| UA90460C2 (ru) | Фармацевтический препарат, который включает антитело против рецептора egf | |
| PE38897A1 (es) | Solucion acuosa de interferon alfa | |
| MX275023B (es) | Champu que contiene una red de gel. | |
| ATE485835T1 (de) | Antikörper enthaltende pharmazeutische lösungen | |
| AR023529A1 (es) | Una composicion champu acondicionadora del cabello y un metodo para acondicionar el cabello | |
| ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
| ES2143507T3 (es) | Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia. | |
| PE20110302A1 (es) | Formulacion farmaceutica de un anticuerpo contra p-selectina | |
| NO20014101L (no) | Stabilisert oral farmasöytisk blanding inneholdende iodid og iodat og fremgangsmåte | |
| MX2021010951A (es) | Composición líquida que comprende un anticuerpo del receptor alfa de interleucina-4 humano. | |
| AU2019339740A8 (en) | CSF-1R antibody formulation | |
| ES2170822T3 (es) | Formulacion liquida de 1,2-bencisotiazolin-3-ona. | |
| DE60336509D1 (de) | Zubereitungen enthaltend sincalide | |
| CA2498233A1 (en) | Clear ophthalmic solution comprising latanoprost as active ingredient | |
| BR0304218A (pt) | ésteres alicìclicos com fragrância de almìscar | |
| AP1696A (en) | Agrochemical formulations comprising ALS inhibitors. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |